Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 9LA: Nivolumab + Ipilimumab + Chemotherapy vs Chemotherapy in Stage IV NSCLC
2023-508757-75-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival. Started Mar 2024; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508757-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508757-75-00.